FORMULATION, BIOAVAILABILITY, AND PHARMACOKINETICS OF SUSTAINED-RELEASE POTASSIUM-CHLORIDE TABLETS

ŞENEL S., ÇAPAN Y., DALKARA T., INANC N., HINCAL A.

PHARMACEUTICAL RESEARCH, cilt.8, sa.10, ss.1313-1317, 1991 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8 Sayı: 10
  • Basım Tarihi: 1991
  • Doi Numarası: 10.1023/a:1015868232590
  • Dergi Adı: PHARMACEUTICAL RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1313-1317
  • Anahtar Kelimeler: POTASSIUM CHLORIDE, SUSTAINED-RELEASE TABLETS, FORMULATION, INVITRO EVALUATION, BIOAVAILABILITY, PHARMACOKINETICS, INVITRO INVIVO EVALUATION
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

The release of potassium chloride incorporated into hydrogenated vegetable oil and hydroxypropyl methylcellulose matrix tablets was studied in vitro. The formulations containing 20% hydrogenated vegetable oil and hydroxypropyl methylcellulose showed a sustained-release profile comparable to that of a standard commercially available sustained-release preparation, containing 8 mEq potassium chloride embedded in a wax material. The formulated and standard sustained-release potassium chloride tablets were compared to a conventional enteric-coated potassium chloride tablet in 10 healthy subjects. Mean recoveries in 24-hr urine potassium levels from four dosage forms (after subtracting normal urine potassium excretion levels) were 76 +/- 32% from hydroxypropyl methylcellulose, 95 +/- 22% from hydrogenated vegetable oil-incorporated matrix tablets, 91 +/- 29% from commercially available sustained-release tablets, and 97 +/- 13% from enteric-coated tablets. There was no significant difference (P > 0.05) in the time to reach maximum excretion rates among the three sustained-release tablets. No significant adverse effect was experienced with any of the preparations.